Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-06 JDQ443 first-line monotherapy in KRAS G12C-mutated NSCLC
2022-001088-29Phase 2Active
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of opnurasib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Novartis. Primary endpoint: Overall response rate. Started Aug 2022; status: active.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-001088-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001088-29.